{
    "id": 22797,
    "fullName": "CALR mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CALR mutant indicates an unspecified mutation in the CALR gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 811,
        "geneSymbol": "CALR",
        "terms": [
            "CALR",
            "cC1qR",
            "CRT",
            "HEL-S-99n",
            "RO",
            "SSA"
        ]
    },
    "variant": "mutant",
    "createDate": "05/19/2016",
    "updateDate": "08/21/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6434,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).",
            "molecularProfile": {
                "id": 23414,
                "profileName": "CALR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4960,
                "name": "bone marrow cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5595,
                    "pubMedId": 26697989,
                    "title": "Myeloproliferative neoplasms: Current molecular biology and genetics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26697989"
                },
                {
                    "id": 5596,
                    "pubMedId": 26449662,
                    "title": "Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26449662"
                },
                {
                    "id": 5597,
                    "pubMedId": 26071474,
                    "title": "The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26071474"
                },
                {
                    "id": 5598,
                    "pubMedId": 25873496,
                    "title": "CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873496"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6433,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).",
            "molecularProfile": {
                "id": 23414,
                "profileName": "CALR mutant"
            },
            "therapy": {
                "id": 1187,
                "therapyName": "Alpha 2 Interferon",
                "synonyms": null
            },
            "indication": {
                "id": 4960,
                "name": "bone marrow cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5594,
                    "pubMedId": 26486786,
                    "title": "Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26486786"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13701,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "CALR mutations are associated with improved survival when compared to JAK2 mutations or concurrent wild-type CALR, MPL, and JAK2 in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 23414,
                "profileName": "CALR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13713,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29393,
                "profileName": "ASXL1 wild-type CALR mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13715,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29395,
                "profileName": "ASXL1 mut CALR mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23414,
            "profileName": "CALR mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29393,
            "profileName": "ASXL1 wild-type CALR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29395,
            "profileName": "ASXL1 mut CALR mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}